Critical role for osteopontin in diabetic nephropathy

Area of Science:

• Nephrology
• Endocrinology
• Molecular Biology

Background:

• Osteopontin (OPN) is a profibrotic molecule elevated in diabetic kidneys.
• Thiazolidinediones (TZDs) reduce albuminuria in diabetic nephropathy (DN) and OPN expression in other tissues.
• The role of OPN in mediating DN remains to be fully elucidated.

Purpose of the Study:

• To investigate if osteopontin (OPN) is a critical mediator of diabetic nephropathy (DN).
• To compare the effects of insulin and TZDs on OPN expression and DN markers.
• To assess the protective effects of OPN deletion in different mouse models of diabetes.

Main Methods:

• Diabetic db/db mice were treated with insulin, rosiglitazone, or pioglitazone.
• Streptozotocin was administered to OPN-null and OPN-wild-type mice.
• OPN-null mice were bred into type 1 (Ins2(akita/+)) and type 2 (db/db) diabetic models.
• In vitro studies used cultured mouse mesangial cells treated with angiotensin II and recombinant OPN.

Main Results:

• TZDs reduced albuminuria and glomerular OPN expression more effectively than insulin in db/db mice.
• OPN deletion significantly decreased albuminuria, mesangial expansion, and extracellular matrix deposition (collagen IV, fibronectin) in diabetic mice.
• OPN deletion also reduced glomerular transforming growth factor-beta (TGF-beta) levels.
• In vitro, TZDs suppressed angiotensin II-induced OPN, while OPN upregulated TGF-beta and MAPK signaling pathways.

Conclusions:

• Osteopontin (OPN) expression exacerbates glomerular damage in diabetic nephropathy (DN) mouse models, partly via TGF-beta.
• Deletion of OPN confers protection against DN progression.
• OPN represents a potential therapeutic target for managing diabetic kidney disease.